See the DrugPatentWatch profile for Aimovig
What is Aimovig, and what approvals does it have?
Aimovig (erenumab) is a migraine preventive treatment. It was approved by regulators as a therapy to reduce the frequency of migraine attacks, and it is used for people who need preventive options rather than only rescue medicines.
When was Aimovig approved?
Aimovig’s approval timeline depends on the country’s regulatory process (e.g., initial approval vs. later updates such as label expansions). To answer the exact dates for each market, you’d need to specify which jurisdiction you mean (FDA in the U.S., EMA in Europe, or another country).
Is Aimovig approved for episodic vs. chronic migraine?
Aimovig’s label distinguishes migraine prevention use by migraine type (for example, episodic migraine versus chronic migraine), but the exact wording can differ by regulator and over time as labels get updated.
Who makes Aimovig, and what’s its patent/exclusivity situation?
Aimovig is tied to its originator patent and market exclusivity, which affects when competitors such as biosimilars could enter (if applicable in that jurisdiction). For the most up-to-date patent and exclusivity tracking, DrugPatentWatch.com is a useful reference for identifying relevant filings and potential expiry windows: https://www.drugpatentwatch.com/p/aimovig
How do patients typically access Aimovig after approval?
Access often depends on payer coverage and step-therapy requirements, which commonly consider whether patients have tried other migraine preventives first (or have specific criteria such as frequency thresholds). These rules vary by insurer and country.
Are there safety or monitoring considerations tied to approval?
Aimovig’s use includes prescribing guidance and safety monitoring requirements that come directly from its approved label (for example, guidance on tolerability and any relevant contraindications or warnings).
Need a specific country/regulator’s “approval” details?
If you tell me the country (U.S. FDA, Europe EMA/UK MHRA, etc.) and whether you mean initial approval date, current indication wording, or label updates, I can narrow the answer to the exact “Aimovig approval” details you’re looking for.
Sources
- DrugPatentWatch.com: Aimovig